Objective-To elucidate whether screening for mutations causing hyperphenylalaninaemia (HPA) and classic galactosaemia could provide important, additional information on a clinical phenotype. Method-Genotypes that cause disease at the phenylalanine hydroxylase (PAH) gene and galactose-1-phosphate uridyltransferase (GALT) gene in a group of 101 hyperphenylalaninaemic and 77 patients with classic galactosaemia were established. The PAH and GALT mutations were identified in genomic DNA extracted from whole blood leucocytes using single stranded conformational analysis and direct fluorescent sequencing of polymerase chain reaction (PCR) products. Results-Mild HPA and mild phenylketonurea (PKU) were caused by divergent genotypes. In the studied group a total of 26 diVerent mild and intermediate PAH mutations were identified, most of them being rare ones. Classic galactosaemia was caused by two frequent mutations, accounting for 82% of all mutated alleles.
Hyperphenylalaninaemia (HPA) is caused by a deficiency of phenylalanine hydroxylase (PAH; EC 1. 14.16 .1) enzyme activity, catalysing conversion of phenylalanine to tyrosine. To date more than 400 diVerent mutations have been characterized in the PAH gene in various ethnic groups. The degree of enzyme impairment is highly variable and depends on the nature and position of mutations. 1 Heterogene-ity at the molecular level is reflected in a range of metabolic and clinical phenotypes, ranging from classic phenylketonuria (PKU) requiring a strict diet low in phenylalanine to mild HPA in which no restriction in phenlyalanine intake is necessary. In mild PKU an optimal dietary regimen must be calculated by assessing the dietary tolerance for phenylalanine. Biochemical and clinical forms of mild HPA could be correlated with genotype. In some cases full diVerential diagnosis of PAH deficiency could take a few months with biochemical and clinical indices. Molecular diagnosis could provide rapid (days) and reliable information about future clinical outcome of a newborn infant.
Classic galactosaemia due to galactose-1phosphate uridyltransferase (GALT; EC 2.7.7.12) enzyme deficiency is an autosomal recessive disease. In galactose metabolism, GALT is a key enzyme which catalyses the interconversion of uridine diphosphoglucose (UDP-glucose) and galactose-1-phosphate with glucose-1-phosphate and uridine diphospho galactose (UDP-galactose). 2 Without GALT activity an infant cannot metabolise galactose-1-phosphate, resulting in kidney, liver, and brain dysfunction. All of the acute neonatal symptoms disappear with implementation of a galactose restricted diet. However, long term complications-such as mental retardation, speech diYculties, and ovarian failure-may still occur. Until today more than 200 diVerent mutations and polymorphisms in the GALT gene were identified. 3 Some of them were connected with mild galactosaemia and biochemical variants of GALT (Duarte-1 and Duarte-2). 4 However, in classic galactosaemia with no GALT activity no obvious relations of clinical outcome to genotype have been established so far.
Patients and methods
Twenty two patients with mild PKU and 79 with mild HPA from unrelated families were diagnosed by the method of Guttler. 5 Phenylalanine tolerance at the age of 5 years in the case of patients requiring dietary treatment, and phenylalanine serum concentrations in patients not requiring diet were included in the classification. 6 The ages of patients ranged from 2 weeks to 26 years.
Seventy seven galactosemic patients from unrelated families were selected on the basis of no measurable GALT activity in red blood cells. In most cases the typical symptoms of galactosaemia-such as jaundice, hepatomegaly, bleeding, sepsis, vomiting, cataract, and failure to thrive (varying in severity and intensity)-were found. There was notably high galactose-1-phosphate concentration (>10 mg/dl) before treatment in every patient.
Clinical outcomes were scored in patients older than 4 years of age as normal or abnormal in areas of intelligence, speech, motor function, growth, cataracts, and ovarian function. 7 In accordance with the criteria of Elsas et al, those patients were considered to have a poor outcome in whom two or more abnormalities had been identified; those with all normal scores were considered to have a good outcome. 7 Patients younger than 4 years of age, diagnosed after 4 months of age, with other complications (most often due to severe neonatal problems-such as kernicterus or hydrocephalus) and those with only one abnormal score, were excluded from the analysis of outcome. The mean age of all the patients was 8.5 years (range 10 months to 20 years).
Isolation of genomic DNA, amplification of PAH and GALT exons, and subsequent direct fluorescent sequencing was done as described previously. In some cases single stranded conformational analysis and heteroduplex analysis preceded sequencing. However, in the case of rare and novel mutations detected, all exons were scanned for sequence changes. Mendelian inheritance of novel mutations was confirmed. Genotypes of all patients were established. All the families gave their consent to molecular diagnosis.
Results
In the group with mild PKU a total of 19 mutations were identified (table 1). Ten mutations were intermediate, seven had been identified previously in diVerent populations and were connected with mild PKU. All patients were compound heterozygotes with an intermediate and a severe mutation. Four intermediate mutations (E390G, Y414C, A104D, and R241H) accounted for 38.6% of all mutated alleles. The remaining six intermediate mutations accounted for 13.8% of mild PKU alleles.
In the mild HPA group a total of 34 mutations were identified, among them 16 mild mutations (table 2) . Fourteen had been identified previously in diVerent populations and had been connected with mild HPA. Almost all patients were compound heterozygotes with a mild and severe mutation, the only one exception was a patient with homozygous genotype for an intermediate V388M mutation. Six mild mutations (A403V, A300S, I306V, R297H, F55L, and V245A) accounted for 39.3% of all mutated alleles. The remaining 10 mild mutations with frequency below 2% accounted for 10% of all mild HPA alleles. 8 9 Genotypes of several patients with ambiguous clinical classification in the neonatal period (age range 2 weeks to 2 months) were established. In most cases mild PKU and mild HPA characteristic genotypes were found; however, in four cases two severe mutations (R408W, IVS10) were found, allowing diagnosis of classic PKU. In one case transient HPA with no PAH mutations was diagnosed. In four patients with mild HPA only one severe mutation was identified at the PAH gene.
In the group with galactosaemia two frequent mutations, Q188R and K285N, accounted for 54% and 28% of 154 mutated alleles, respectively (table 3) . The remaining 16 mutations were found in 18% of alleles, among them IVS3nt-2a→c (c.329-2a→c) was relatively frequent (4.5%). In the group seven novel mutations were identified. No obvious correlation between genotype and clinical 
Mild mutations are in bold. *Novel mutations: R71H=c.212G→A; P89S=c.265C→T; IVS4=c.441+5g→t; IVS2=c.168+5g→a; IVS12=c.1315+1g→a. course of classic galactosaemia was found, except mutation K285N in homozygosity (see later). 10 Various clinical outcomes were found even in patients homozygous for mutations Q188R, K285N, or IVS3nt-2a→c.
In one patient (not included in the table 3) with no GALT activity three diVerent mutations were identified: K285N, E271G (c.812 A→G), and I378V(c.1132A→G). Both mutations, E271G and I378V are novel ones. The I378V mutation changed the penultimate GALT codon, and the substitution was a conservative one, so it could be speculated that I378V is a silent polymorphism.
Sixty three patients with galactosaemia out of a total of 77 fulfilled the criteria of Elsas for evaluation of clinical outcome. Twenty of 63 subjects had a good outcome and 43 of 63 had a poor outcome. In 46 of 63 patients the Q188R mutation was identified. Twenty one patients had the Q188R/Q188R genotype, 15 had the Q188R/K285N genotype, and the remaining 10 had the Q188R mutation connected with other mutations on the second allele. Good clinical outcome was seen in six patients homozygous for the Q188R mutation, in six patients with the Q188R/K285N genotype and in three patients with the Q188R/ diVerent mutation genotype.
The K285N mutation was identified in 29 of 63 evaluated patients. Seven patients were homozygous for the K285N mutation, 15 patients had the Q188R/K285N genotype, and seven carried the K285N mutation in connection with diVerent mutations. Good outcome was seen only in one patient homozygous for the K285N mutation and in two patients with the K285N/diVerent mutation.
Two out of three patients carrying diVerent mutations on both alleles (non-Q188R, non-K285N) had a good clinical outcome.
Poor clinical outcomes were found in 15 patients homozygous for the Q188R mutation, six homozygous for the K285N mutation, nine patients with the Q188R/K285N, seven with the Q188R/other mutation, five with the K285N/other, and one with other/other geno-types. There was no significant diVerence by clinical outcomes among two prevalent mutations Q188R and K285N (Fisher's exact test p=0.7254)
Discussion
The range of mutations causing mild forms of HPA as well as classic galactosaemia is heterogeneous in Poland. However, the situation is diVerent in both groups because of strong association between mild and intermediate mutations and clinical phenotype at the PAH gene. 11 Among 16 mild mutations identified, 14 are connected with mild HPA in diVerent populations. In the group with mild PKU, seven out of 10 intermediate mutations have been identified all over the world. 12 Novel mutations were connected with mild HPA forms either on the basis of in vitro analysis (R68G) or with the in vitro assessment method. 13 14 It could be concluded that neonatal biochemical screening for HPA remains the most eVective and cost beneficial strategy for detection of new cases of mild PAH deficiency. Molecular diagnostics help in rapid diVerential diagnosis in the neonatal period and may provide additional information for anticipating dietary treatment. Particularly in premature children, phenylalanine values are sometimes increased possibly due to enzyme immaturity, and such "transient HPA" could interfere with initial diagnosis. A reverse situation is also found, as stated in the results section, and initial diagnosis of mild HPA could be changed after a few months to classic PKU. Genotyping could show such cases immediately.
In four patients with well established mild HPA phenotype only one severe mutation at the PAH gene was identified (not included in table 2). In those cases all the exons (including exon 13 and 5' untranslated region to the position -135) with flanking intronic sequences were scanned. It is possible that a mutation causing disease is located in distant intronic sequences. It could be speculated also that mild HPA is caused by mutations located outside the PAH locus. Mutations in the pterin-4a-carbinolamine dehydratase (PCDH) and 6-pyruvoyltetrahydropterin synthase (PTS) genes are known to produce mild HPA. However, in two of the patients all the exons of PCDH and PTS genes were checked and no sequence variation was found.
It was suggested previously that a useful method for detection of a PAH mutation after biochemical analysis is scanning of the whole coding region by denaturing gel electrophoresis, stranded conformational analysis, or heteroduplex analysis. 15 An alternative approach is sequencing of all the exons or step by step sequencing of exons in order of the prevalence of mutations. In this case a cost of an automated fluorescent cyclic sequencing for a patient is about 300 ECU (US$ 260) in Poland.
A diVerent situation is found for classic phenylketonuria. In a group of 89 patients with classic PKU, the 14 most common mutations in Central Europe were screened for with (table 4) . These results were published previously. 16 17 One mutation (R408W) was found to predominate, accounting for 55.6% of mutated alleles. The other three mutations accounted for 14.54% of alleles. Frequencies of the other four mutations were below 2.5%, however, all of them were located in exon 7, which enables direct sequencing in detection. No clinically useful correlation between genotype and phenotype was found in the group of patients with classic PKU.
The only exception was the R261Q mutation, associated with good intellectual outcome despite high phenylalanine concentrations. This mutation was found in a family with maternal PKU and in other patients with variant PKU and high intelligence scores in Poland (results not shown). Thus it may be desirable to screen for this particular mutation in patients with classic PKU, as in this case more careful evaluation of a patient's outcome and possibly a less restrictive dietary treatment could be proposed. 18 Similarly, substantially no clinically important correlation between genotype and phenotype was found in a group of patients with classic galactosaemia.
Among 26 patients homozygous for the Q188R mutation 15 (aged 6-29 years) had a poor outcome, six had, as yet, a good outcome (aged 4-10 years), and five were younger than 2 years of age. The outcome did not depend on the age at diagnosis, severity of illness in the neonatal period, or galactose-1-phosphate concentrations during treatment.
Comparison of the two prevalent mutations (Q188R and K285N) showed that poor clinical outcome aVects 67% of patients who carried the Q188R mutation and 68% who carried the K285N mutation. There is no significant diVerence between these two groups (Fisher's exact test).
However, it seems that patients homozygous for the K285N mutation more often have mental retardation and pronounced speech abnormalities than patients with the Q188R/Q188R genotype. These problems were found in six out of seven patients evaluated with the K285N/ K285N genotype. The youngest of these was not assessed for outcome, is now aged 2.5 years, is retarded, and does not yet talk.
These findings require further confirmation because of diVerent numbers of patients homozygous for the Q188R and K285N mutations (21 and seven respectively).
It was well recognised that in the case of galactosaemia, clinical phenotype is likely to depend on many factors, including endogenous production of galactose, capacity to oxidise galactose, alternative pathways of galactose catabolism, and residual GALT activity. Genotyping could be helpful, but should be combined with comprehensive biochemical analysis. 19 A patient with the S135L/Q188R genotype identified in the reported group. She presented classic galactosaemia, with no measurable GALT activity in the red blood cells. However, previously the S135L mutation has been associated with milder forms of galactosaemia and considerable GALT residual activity in the liver and intestinal mucosa.
Occasionally genotyping could show double mutated alleles in patients with galactosaemia. The importance of this for genetic counselling is limited to cases with a mild mutation.
A recent paper on genetic screening for PAH deficiency in Italy showed that molecular diagnosis does not increase the sensitivity and the benefit:cost ratio of PKU screening. Authors of the paper do not recommend molecular diagnosis for use in Italy, however, they did not initially diVerentiate between the forms of HPA. 20 Our results on HPA and galactosaemia in a Polish population show that molecular diagnosis of HPA could be beneficial, however, it should be preceded by biochemical analysis and implemented to diVerentiate mild forms of HPA and cases of ambiguous clinical outcome. 21 The suggested method could be direct, fluorescent, automated DNA sequencing.
Molecular diagnosis of classic PKU and classic galactosaemia is controversial and is not recommended. In both groups limited clinically important information could be inferred from genotyping. 
